

VRL/SEC/EXCHANGE

12.08.2021

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai Script Code: 526953
--	---

Sub: Submission of Unaudited Financial results for the quarter ended on 30.06.2021

Dear Sir/Madam,

Please find enclosed herewith Unaudited Financial Results for the quarter ended on 30.06.2021 along with Limited Review report which were taken on record by the Board of Directors at its meeting held on 12.08.2021.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for **VENUS REMEDIES LIMITED**



Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

Independent Auditor's Limited Review Report On Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To the Board of Director of
VENUS REMEDIES LIMITED**

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the Quarter ended 30th June, 2021 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to report a conclusion on these statements based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Head Office:
4696 Bnj Bhawag
21A Ansen Road
Darya Ganj,
New Delhi-110002, INDIA
Tel : +91-11-2328-8101

Corporate Office:
GLOBAL BUSINESS SQUARE
Building No. 32, Sector 44,
Institutional Area Gurgaon,
122003, India
Tel : +91-124-4786-200

Nehru Place:
503, Chiranjiv Tower,
43, Nehru Place
New Delhi 110019, India
+91-11-2622-3712,
2622-6933

Mumbai:
GR - 108,,
WeWork Vijay Diamond,
No. A38B2, B Cross Road
Marol Industrial Area,
MIDC, Andheri (East)
Mumbai - 400093

Karol Bagh:
17A/55, Triveni Plaza,
Gurudwara Road,
Karol Bagh,
New Delhi- 110005
Tel : +91-11-4504-4453

Chandigarh:
SCO-705/1st Floor
NAC Manimera
Chandigarh-160101, India
Tel : +91-172-507-7789,
5077-790



4. Emphasis of matter:

We draw attention to note no.5 of the standalone financial results with respect to review of liability related to FCCB bonds amounting to US \$ 4.59 million in the absence of any explicit agreement and based on reassessment of liability in terms of the provisions of The Limitation Act, 1963. Accordingly the carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015, as the FCCB Bonds liability becoming time barred, as per a legal opinion obtained by the Company. The provision of interest made from 1st February 2015 till 31st March, 2019 of Rs.68.60 Million was also written back during financial year 2019-20.

Our conclusion is not modified in respect of above matter.

For Vinod Kumar & Associates
Chartered Accountants
FRN-002304N


Mukesh Dadhich
Partner

M.No. 511741

UDIN: 21511741AAAAJP9723

Date: 12th August, 2021



**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH JUNE, 2021**

S. No.	PARTICULARS	(Rs. in Millions)			
		QUARTER ENDED ON			YEAR ENDED ON
		30-06-2021	31-03-2021	30-06-2020	31-03-2021
		Unaudited	Audited	Unaudited	Audited
1	Revenue				
	(a) Revenue from Operations	1388.48	1024.40	1797.10	5146.23
	(b) Other Income	19.18	33.63	15.07	177.62
	Total Income	1387.66	1058.03	1812.17	5,323.85
2	Expenses				
	(a) Cost of Material Consumed	1088.32	795.06	1225.44	3440.44
	(b) Changes in inventories of finished goods, work-in-progress, Stock in Trade	(173.99)	(119.71)	(48.65)	(73.56)
	(c) Employee benefits expense				
	(d) Finance Cost	105.73	83.23	87.98	358.88
	(e) Depreciation & amortization expense	-	8.67	27.94	127.28
	(f) Selling, Manufacturing and Administrative expenses	83.67	91.76	83.33	342.80
	(g) Research & Development expenses	146.42	143.57	287.73	793.19
	Total Expense	28.38	43.69	36.63	158.65
3	Profit before exceptional items and taxes (1-2)	1,258.53	1,046.17	1,700.40	5,147.66
	EBIDTA (3+2d+2e)	129.13	11.86	111.77	176.19
4	Exceptional Items	212.80	112.29	223.04	646.26
5	Profit before tax (3 +/- 4)	-	205.53	(91.70)	234.42
6	Income Tax Expense /Deferred Tax(Benefits)	129.13	217.39	20.07	410.81
7	Net Profit / (Loss) for the period (5- 6)	(16.77)	(189.12)	-	(132.12)
8	Other Comprehensive income (Net of taxes)	145.90	386.51	20.07	542.72
A	(i) Items that will not be classified to profit & loss				
B	(ii) Items that will be classified to profit & loss	(0.24)	0.69	-	(0.95)
	Total other comprehensive income Net of Income Tax	(0.24)	0.69	-	(0.95)
9	Total comprehensive income for the period (7+8)	145.66	387.20	20.07	541.78
10	Paid up equity share capital (Face Value of Equity Shares)	133.67	123.42	123.42	123.42
11	Other Equity	10	10	10	10
12	Earning per share (of Rs. 10/- each) (Not annulzed)				3,878.41
	(a) Basic	11.06	31.32	1.63	43.97
	(b) Diluted	11.06	31.32	1.63	43.97





Notes to the financial results:-

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 12, 2021. The statutory auditors of the company have carried out limited review of the above standalone Financial Results for the Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The financial results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
3. During the period under review, the company had made allotment of 10,25,000 fully paid-up equity shares pursuant to conversion of 10,25,000 "Fully Convertible Warrants" on 31st May, 2021.
4. The Company has taken into account external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including recoverability of its assets.
5. The FCCB bonds of US \$ 4.59 Million became due for maturity on 1st February, 2015. The bondholder(s) or their custodian bank did not submit the bonds for conversion or redemption. FCCB Bonds liability becoming time barred in terms of the provisions of The Limitation Act, 1963, as per a legal opinion obtained by the parent Company. The carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015. The board of directors in their meeting held on 31st May, 2021 have decided that a request letter be submitted to Reserve Bank of India in regard to FCCB to seek further course of action on the same.



6. The Code of Social Security 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period in which the Code becomes effective.
7. Figures of the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year and unaudited published figures up to nine months of the relevant financial year.
8. Previous year / period figures have been regrouped/ reclassified wherever necessary.
9. The Company has only one reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors

For VENUS REMEDIES LIMITED


Pawan Chaudhary
(Managing Director)



Din: 00435503

Date: 12-08-2021



Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated financial results of VENUS REMEDIES LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To
The Board of Directors of
VENUS REMEDIES LIMITED

1. We have reviewed the accompanying consolidated financial results of **VENUS REMEDIES LIMITED ("the Parent")** and its subsidiary (**collectively referred to as 'the Group'**), for the Quarter ended 30th June 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
3. The Statement includes the results of the following Subsidiary:
 - i. Venus Pharma GmbH
4. Based on our review conducted and procedures performed as stated in paragraph 2 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Head Office:
4696 Brij Bhawan,
21A Ansari Road,
Darya Ganj,
New Delhi-110002, INDIA
Tel: +91-11-2328-8101

Corporate Office:
GLOBAL BUSINESS SQUARE
Building No 32, Sector 44,
Institutional Area Gurgaon,
122003, India
Tel: +91-124-4786-200

Nehru Place:
503, Chiranjiv Tower,
43, Nehru Place
New Delhi 110019, India
+91-11-2622-3712,
2622-8933

Mumbai:
GR - 10B,
WeWork Vijay Diamond,
No. A3882, 8 Cross Road
Marol Industrial Area,
MIDC, Andheri (East)
Mumbai - 400093

Karol Bagh:
17A/55, Triveni Plaza,
Gurudwara Road,
Karol Bagh,
New Delhi- 110005
Tel: +91-11-4504-4453

Chandigarh:
SCO-705, 1st Floor,
NAC Main Market
Chandigarh-160101, India
Tel: +91-172-507-7789,
5077-790



5. Emphasis of matter

We draw attention to note no.5 of the consolidated financial results with respect to review of liability related to FCCB bonds amounting to US \$ 4.59 million in the absence of any explicit agreement and based on reassessment of liability in terms of the provisions of The Limitation Act, 1963. Accordingly the carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015, as the FCCB Bonds liability becoming time barred, as per a legal opinion obtained by the Parent Company. The provision of interest made from 1st February 2015 till 31st March, 2019 of Rs.68.60 Million was also written back during financial year 2019-20.

Our conclusion is not modified in respect of above matter.

6. Other Matter

We did not review the interim financial results and other financial information of a subsidiary included in the Statement, whose interim financial results and other financial information reflect total revenues of Rs. 153.05 Million, total net (loss) after tax of Rs. (28.92) Million and total comprehensive (loss) of Rs.(28.92) Million for the quarter ended 30th June 2021, as considered in the consolidated unaudited financial results. These interim financial results and other financial information have been reviewed by other auditor whose report have been furnished to us by the management and our observations on the Statement, in so far as it relates to the amounts and disclosures included in respect of such subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 2 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Vinod Kumar & Associates

Chartered Accountants

FRN-002304N


Mukesh Dadhich

Partner

M.No. 511741

UDIN: 21511741AAAAJQ3541

Date: 12th August, 2021



STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

Rs. in Millions

S. No.	PARTICULARS	QUARTER ENDED ON			YEAR ENDED ON
		30-06-2021	31-03-2021	30-06-2020	31-03-2021
		Unaudited	Audited	Unaudited	Audited
1	Revenue				
	(a) Revenue from Operations	1298.11	1113.71	1887.45	5481.23
	(b) Other Income	19.54	34.92	20.35	196.30
	Total income	1317.65	1148.63	1907.80	5,677.53
2	Expenses				
	(a) Cost of Material Consumed	1148.90	795.83	1259.49	3479.40
	(b) Changes in inventories of finished goods, work-in-progress, Stock in Trade	(355.29)	(45.29)	-56.61	(71.47)
	(c) Employee benefits expense	127.64	106.05	115.22	460.19
	(d) Finance Cost	1.41	9.61	28.53	130.19
	(e) Depreciation & amortization expense	86.23	93.81	85.89	352.76
	(f) Selling, Manufacturing and Administrative expenses	180.18	189.65	327.21	917.77
	(g) Research & Development expenses	28.38	42.52	36.63	157.58
	Total Expense	1,217.45	1,172.18	1,796.36	5,426.42
3	Profit before exceptional items and taxes (1-2)	100.20	(23.55)	111.44	251.11
	EBIDTA (3+2d+2e)	187.84	79.87	225.86	734.06
4	Exceptional items	-	205.53	(91.71)	234.42
5	Profit before tax (3 +/- 4)	100.20	181.98	19.73	485.53
6	Income Tax Expense /Deferred Tax(Benefits)	(16.77)	(169.12)	-	(132.12)
7	Net Profit / (Loss) for the period (5- 6)	116.97	351.10	19.73	617.65
8	Other Comprehensive Income (Net of taxes)				
A	(I) Items that will not be classified to profit & loss	(0.24)	0.69	-	(0.95)
B	(II) Items that will be classified to profit & loss	-	-	-	-
	Total other comprehensive income Net of Income Tax	(0.24)	0.69	-	(0.95)
9	Total comprehensive Income for the period (7+/-8)	116.73	351.79	19.73	616.70
10	Paid up equity share capital (Face Value of Equity Shares)	133.67	123.42	123.42	123.42
11	Other Equity	10	10	10	10
12	Earning per share (of Rs. 10/- each) (Not annualized)				
	(a) Basic	8.86	28.45	1.60	50.04
	(b) Diluted	8.86	28.45	1.60	50.04





Notes to the financial results:-

1. The above consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 12, 2021. The statutory auditors of the company have carried out limited review of the above Financial Results for the Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The consolidated financial results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
3. During the period under review, the parent company had made allotment of 10,25,000 fully paid-up equity shares pursuant to conversion of 10,25,000 "Fully Convertible Warrants" on 31st May, 2021.
4. The group has taken into account external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including recoverability of its assets.
5. The FCCB bonds of US \$ 4.59 Million became due for maturity on 1st February, 2015. The bondholder(s) or their custodian bank did not submit the bonds for conversion or redemption. FCCB Bonds liability becoming time barred in terms of the provisions of The Limitation Act, 1963, as per a legal opinion obtained by the parent Company. The carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015. The board of directors in their meeting held on 31st May, 2021 have decided that a request letter be submitted to Reserve Bank of India in regard to FCCB to seek further course of action on the same.



6. The Code of Social Security 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The group will assess the impact of the Code when it comes into effect and will record any related impact in the period in which the Code becomes effective.
7. Figures of the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year and unaudited published figures up to nine months of the relevant financial year.
8. Previous year / period figures have been regrouped/ reclassified wherever necessary.
9. The group has only one reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors

For VENUS REMEDIES LIMITED


Pawan Chaudhary



(Managing Director)

Din: 00435503

Date: 12-08-2021

